• Entrada Therapeutics released positive topline results already reported from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study in Duchenne muscular dystrophy.
• The initial-dose cohort met the main goal on safety and tolerability, supporting continued dose escalation in later cohorts.
• Early biological activity was observed, though no functional improvement was expected or seen at this stage.
• Enrollment is complete for Cohort 2 at a higher dose, with data scheduled for the first half of 2027.
• The program targets a once-every-six-weeks dosing schedule, positioning it as a lower-frequency alternative to current weekly regimens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140700PRIMZONEFULLFEED9845174) on October 14, 2026, and is solely responsible for the information contained therein.